Company / R&D Expense
Corcept Therapeutics Incorporated R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$254.9M
FY2025
5-year range
$113.9M / $254.9M
FY2021-FY2025
Trend
+3.2%
vs FY2024
Sector context
#71 of 210
Health Care
What the data says
At $255M, Corcept Therapeutics Incorporated's r&d expense ranks #71 of 210 in the Health Care sector. R&D Expense has increased for 4 consecutive years, from $114M in FY2021 to $255M in FY2025.
Based on SEC 10-K filings.
$255M in FY2025 with a 5-year CAGR of +17.3%.
Improved from $184M to $255M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +24.8%
- 5-Year CAGR
- +17.3%
- 10-Year CAGR
- -
Sector benchmark
#71 of 210 in Health CareTop 34% of 210This company $254.9M Sector average $644.1M
▼
-60.4% below sector average
Key checks
Key Insights
- Corcept Therapeutics Incorporated's r&d expense has grown for 4 consecutive years.
- 5-year CAGR of +17.3%, indicating consistent growth.
- In FY2025, r&d expense increased 3.2% year-over-year.
- Ranks #71 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $254.9M | +3.2% |
| FY2024 | $246.9M | +33.9% |
| FY2023 | $184.4M | +40.7% |
| FY2022 | $131.0M | +15.0% |
| FY2021 | $113.9M | -0.8% |
| FY2020 | $114.8M | +184.2% |
| FY2019 | $40.4M | +69.3% |
| FY2018 | $23.8M | -40.9% |
| FY2017 | $40.4M | +119.8% |
| FY2016 | $18.4M | +19.2% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026